Jean Pierre Bizzari - Aug 23, 2023 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
Director
Signature
/s/ John Hamill, as Attorney-in-Fact
Stock symbol
APRE
Transactions as of
Aug 23, 2023
Transactions value $
$0
Form type
4
Date filed
8/24/2023, 09:47 PM
Previous filing
May 9, 2023
Next filing
Jan 2, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Stock Options (Right to Buy) Award $0 +12.5K $0.00 12.5K Aug 23, 2023 Common Stock 12.5K $3.65 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options shall vest in full on the two year anniversary of the grant date, subject to the reporting person's continued service on the Issuer's board of Directors through and including the applicable vesting date.